title: Additive benefit of PGI2 and PGE1 (via different mechanisms?) on inhibition of activation of human vascular smooth muscle cells?
abstract: It seems likely that the antiplatelet action of antiaggregatory prostaglandins (PGE1, PGI2) is not the pivotal mechanism of action involved in clinical improvement of peripheral vascular disease. Based upon earlier results that both of these agents may have a certain effect on proliferation of vascular smooth muscle cells, we approached that question of an "optimal therapeutic regimen" going one step further. Patients having to undergo amputation were given a randomized "last choice" therapy with either PGI2 (once or twice a day, 6 h, 5 ng/kg/min i.v.), PGE1 (once or twice a day, 1 ng/kg/min i.a.) or a combination of both with a 6 h interval in between for 5 consecutive days. The ones who underwent surgery had a pathomorphological examination of vascular segments removed during amputation. The counting of activated smooth muscle cells indicates a significant drop induced by both of the PG's alone. A second infusion a day with the same compound, however, did not induce a further decrease in the activation state. In contrast administering the complimentary PG caused a comparable, significant decrease (p less than 0.01) in activation of smooth muscle cells in the intima and the media as well. It thus seems, that different mechanisms may be involved inducing additive therapeutic benefit. PGI2 is hypothesised to act predominantly by blocking PDGF-release and interference with PDGF, whereas PGE1 may have a more direct vascular action. From these findings, as well as the beneficial clinical results to be reported elsewhere, a combined therapy by the infusion scheme used may be the optimal one for a PG-therapy at the moment, based upon platelet and smooth muscle cell action.
authors.affiliation: Atherosclerosis Research Group (ASF) Vienna.
authors.forename: H
authors.initials: H
authors.lastname: Sinzinger
authors.forename: P
authors.initials: P
authors.lastname: Fitscha
authors.forename: O
authors.initials: O
authors.lastname: Wagner
authors.forename: J
authors.initials: J
authors.lastname: Kaliman
authors.forename: T
authors.initials: T
authors.lastname: Zidek
authors.forename: W
authors.initials: W
authors.lastname: Rogatti
mesh_terms: D000367:Age Factors; D000527:Alprostadil / Q000008:administration & dosage / Q000494:pharmacology*; D002452:Cell Count; D004357:Drug Synergism; D011464:Epoprostenol / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007262:Infusions, Intravenous; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects*
chemical_list: D011464:Epoprostenol; D000527:Alprostadil